Every lot published · search any lot number before you order

Retatrutide 4 mg: Phase 2 and Phase 3 Research Arms

The Phase 2 obesity trial reported −17.1% mean weight change at 48 weeks in the combined 4 mg groups. The sponsor’s TRIUMPH-1 efficacy analysis reported −19.0% at 80 weeks in the 4 mg arm.

Retatrutide 4 mg: Phase 2 and Phase 3 Research Arms. Same number, different protocols. Assigned amount, Trial protocol, Group result. GLP LIFE SCIENCES · RESEARCH BRIEF 23 Same number, different protocols Dosage research Assigned amountTrial protocolGroup result
Same number, different protocols. Illustration for this research brief.

Same number, different protocols

The time points, protocols and populations differ. The second figure should not be treated as a continuation of the first cohort or as a calculation of additional weight loss between weeks 48 and 80.

How to interpret the evidence

Use the trial names alongside the amounts. A shared target amount alone does not make the findings directly comparable.

This series reports assigned research arms for interpreting study results. Retatrutide is investigational, and clinical-trial amounts are not dosing instructions.

Sources